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Abstract
Background: Propolis, an ancient herbal medicine, has been reported the beneficial effect both in
asthma patients and murine model of asthma, but the mechanism was not clearly understood. In
this study, the effect of caffeic acid phenethyl ester (CAPE), the most extensively studied
components in propolis, on the functions of human monocyte-derived dendritic cells (MoDCs) was
investigated.
Results: CAPE significantly inhibited IL-12 p40, IL-12 p70, IL-10 protein expression in mature
healthy human MoDCs stimulated by lipopolysaccharides (LPS) and IL-12 p40, IL-10, IP-10
stimulated by crude mite extract. CAPE significantly inhibited IL-10 and IP-10 but not IL-12
expression in allergic patients' MoDCs stimulated by crude mite extract. In contrast, the
upregulation of costimulatory molecules in mature MoDCs was not suppressed by CAPE. Further,
the antigen presenting ability of DCs was not inhibited by CAPE. CAPE inhibited IκBα
phosphorylation and NF-κB activation but not mitogen-activated protein kinase (MAPK) family
phosphorylation in human MoDCs.
Conclusion: These results indicated that CAPE inhibited cytokine and chemokine production by
MoDCs which might be related to the NF-κB signaling pathway. This study provided a new insight
into the mechanism of CAPE in immune response and the rationale for propolis in the treatment
of asthma and other allergic disorders.
Background
Asthma is the leading chronic disease in children. Recent
advance of asthma medication has decreased the mortal-
ity and morbidity of asthma. Among them, inhaled corti-
costeroid is the mainstay treatment. Other medications
such as theophylline, long-acting beta2-adrenergic ago-
nist, leukotriene modifier and anti-IgE treatment, alone or
in combination of inhaled corticosteroid, have increased
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the control of asthma. However, these drugs do have some
side effects such as oral thrush, inhibition of growth[1] or
increased risk of severe asthma exacerbation [2]. Difficult-
to-treat asthma patients do still have persistent symptoms
even with the best therapy [3]. Therefore, several other
approaches to asthma treatment are extensively studied.
The subcutaneous immunotherapy has some effect but
the anaphylactic side effect and frequent injection limit
the application [4]. Sublingual immunotherapy, which
was safe in children, has only low to moderate clinical
efficacy in mild to moderate persistent asthma [5,6].
Other novel treatments in murine model of asthma, such
as central deoxycytidyl-deoxyguanosine (CpG) dinucle-
otide inhalation, DNA vaccination and antisense oligonu-
cleotide are not yet proved in human [7].
Propolis, the natural resinous products collected by hon-
eybees from various plant sources, is well known for the
management of respiratory problems in herbal medicine
[8]. In clinical studies, Khayyal et al. administered the
aqueous extract of propolis to patients with mild to mod-
erate asthma daily for 2 months in combination with oral
theophylline [9]. They found that the number of noctur-
nal asthma attacks decreased significantly in the propolis
treatment group compared to the placebo group. In addi-
tion, the lung function of patients treated with propolis
improved after 2 months while the placebo group did not.
Finally, the sera of patients in the propolis group had sig-
nificantly lower levels of tumor necrosis factor (TNF)-α,
intercellular adhesion molecule (ICAM)-1, interleukin
(IL)-6, IL-8, leukotrienes and prostaglandin (PG)E2 after
the 2 months treatment period, but these changes were
not identified in the placebo group. In murine model of
asthma, propolis extracts could suppress the serum levels
of OVA-specific IgE and IgG1, and airway hyperrespon-
siveness in OVA-sensitized mice. Besides, interferon
(IFN)-γ, IL-6, and IL-10 secretion in OVA-stimulated
splenocytes from the propolis groups was significantly
lower than that of the control group [10].
The composition of propolis is highly variable, depending
on the local plant, and is reported to contain approxi-
mately 50% resin and vegetable balsam, 30% wax, 10%
essential and aromatic oils, 5% pollen, and 5% other sub-
stances (minerals) [8]. Further, propolis contains a mix-
ture of biologically active chemicals including terpenes,
cinnamic acid, caffeic acid and their esters, amino acids
and flavonoids [11]. Caffeic acid phenethyl ester (CAPE),
one of the most extensively studied components in prop-
olis, is reported to have anti-tumor [12,13], anti-inflam-
matory [14,15] and antioxidant [16] properties. CAPE has
also been found to suppress eicosanoid synthesis [14]. In
immunological studies, CAPE is a potent inhibitor of
mitogen-induced T cell proliferation, lymphokine pro-
duction [17] and nuclear factor (NF)-κB activation [18-
20]. CAPE modulated nuclear binding of the NF-κB subu-
nit p65/RelA, decreased expression of cytosolic IκBα [19]
and inhibited NFAT dephosphorylation and transcrip-
tional activity [20] in T cells.
Dendritic cells (DCs), one of the most potent professional
antigen-presenting cells (APCs), play an important role in
the pathogenesis of asthma and allergic rhinitis [21]. DCs
normally reside in the airway mucosa and interstitium in
an immature state [22] and are specialized in capturing
and processing antigens to form major histocompatibility
complex (MHC) peptide complexes. Upon antigen or
other stimulation, DCs mature with loss of endocytic/
phagocytic receptors, upregulation of MHC molecules
and costimulatory molecules, alterations in adhesion
molecule and cytokine receptor expression and cytokine
production, and changes in morphology [23-27]. At the
same time, the DCs migrate to the draining lymph nodes
and present captured antigen to naïve T lymphocytes [23]
by a stable, long-lasting immunologic synapse with T
cells. MHC peptide interacts with the T cell receptors, cos-
timulatory molecules interact with T cell-expressed core-
ceptors, and cytokines are released to polarize the T-cell
response [28], thus results in the allergic airway inflam-
mation. The role of DCs in the secondary immune
response is further supported by the fact that their deple-
tion at the time of allergen challenge abrogated all the fea-
tures of asthma in murine model of asthma, including
airway inflammation, goblet cell hyperplasia, and bron-
chial hyperresponsiveness [29].
Since Khayyal et al. demonstrated the beneficial effect of
propolis in asthma patients [9] and Sy et al. reported the
similar effect in murine model of asthma [10], we became
interested in studying the impact of CAPE on dendritic
cells in the pathogenesis of asthma. There was only one
study that surveyed the immunosuppressive activity of
CAPE on human DCs, which showed that CAPE blocked
the L. major-induced IRF-1, IRF-8, IL-12 p35 and IL-12
p40 RNA expression in human MoDCs by quantitative
real time RT-PCR as well as the IRF-8 nuclear translocation
[30]. However, mite and pollens, instead of L. major, are
the major allergens in allergic disease. In the present
study, the authors investigated whether CAPE has regula-
tory effect on the cytokine and chemokine production and
antigen presentation ability in mite stimulated human
MoDCs. It is anticipated that this study would establish
the role of CAPE on the function of DCs and might pro-
vide insight into the mechanisms of action and rationale
of propolis administration in the management of asthma
and other allergic disorders.
Results
CAPE inhibited cytokine and chemokine production in 
humanMoDCs
The IL-12 p40, IL-12 p70, IL-10 and IFN-γ-inducible pro-
tein (IP)-10 levels in the supernatants from non-atopicBMC Immunology 2009, 10:39 http://www.biomedcentral.com/1471-2172/10/39
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healthy subjects and mite-sensitized allergic patients were
analyzed by ELISA (Figure 1). In healthy subjects, LPS
stimulated MoDCs to secrete large amount of IL-12 p40,
IL-10 and IP-10 (P < 0.001) compared to control MoDCs
and crude mite extract stimulated MoDCs to secrete large
amount of IL-12 p40 and IP-10 (P < 0.001). In allergic
patients, LPS stimulated MoDCs to secrete higher IL-12
p70, IL-10 and IP-10 (P = 0.018, 0.002, < 0.001, respec-
tively), and crude mite extract stimulated MoDCs to
secrete higher IL-10 and IP-10 (P < 0.001) than control
MoDCs. However, LPS stimulated DCs from allergic
patients to secrete less IL-12 p40 and IL-10 (P = 0.002,
0.037, respectively) compared to those from healthy sub-
jects. Crude mite extract stimulated DCs from allergic
patients to secrete less IL-12 p40 (P = 0.046) but higher IL-
10 (P = 0.003) than those from healthy subjects.
To determine whether CAPE could alter cytokine and
chemokine production in human MoDCs, cytokine and
chemokine levels of MoDCs cultured for 48 hours under
LPS or crude mite extract stimulation in the absence or
presence of CAPE were compared. In healthy subjects,
CAPE significantly inhibited the IL-12 p40, IL-12 p70 and
IL-10 production stimulated by LPS (P = 0.001, 0.011,
0.003, respectively). Further, CAPE significantly inhibited
the IL-12 p40, IL-10 and IP-10 production stimulated by
crude mite extract (P = 0.044, 0.022, < 0.001 respectively).
IL-12 p70 production stimulated by crude mite extract
was also inhibited by CAPE, but this result was not statis-
tically significant (P = 0.088). In allergic patients, CAPE
could only significantly inhibit the IL-10 and IP-10 pro-
duction from patients' MoDCs stimulated by crude mite
extract (P = 0.030, 0.002 respectively).
CAPE did not alter the upregulation of surface markers on 
mature MoDCs
To determine whether CAPE could modulate the matura-
tion of human MoDCs in vitro, the phenotype of MoDCs
from healthy subjects treated as described above was
assessed via analysis of surface markers by flow cytometry
(Figure 2). Compared to control MoDCs, MoDCs treated
with LPS had increased expression of HLA-DR, CD86,
CD80 and CD83 (P = 0.007, 0.005, <0.001 and 0.006
respectively) and MoDCs treated with crude mite extract
had increased expression of HLA-DR, CD86 and CD80 (P
= 0.007, 0.018 and 0.020, respectively). In contrast, the
costimulatory molecules (CD86, CD80, CD83) and MHC
class II molecules were not significantly inhibited by
CAPE treatment.
CAPE did not alter the antigen uptake ability of mature 
MoDCs
Immature DCs capture antigens through phagocytosis,
macropinocytosis and adsorptive endocytosis. Then they
become mature DCs and lose their ability of antigen
uptake [31]. The uptake of FITC-dextran is known to be
maximal in the immature human MoDCs through mac-
ropinocytosis and mannose receptor [32]. To determine
whether CAPE could modulate the antigen uptake ability
of human MoDCs, FITC-dextran was analyzed by flow
cytometry (Figure 3). In healthy subjects, the LPS and
crude mite extract-treated MoDCs had decreased ability of
FITC-dextran uptake compared to control MoDCs. How-
ever, CAPE did not alter the phagocytic capacity in human
MoDCs.
CAPE did not alter the T cell activation co-cultured with 
LPS or mite-treated human MoDCs
Mature DCs have the capacity to induce proliferation and
cytokine production in T cells [27]. In the present study,
autologous naïve CD4+ T cells was employed in an activa-
tion assay to determine if CAPE treated MoDCs have a
decreased ability to activate T cells. The treated MoDCs
were co-cultured with autologous naïve CD4+ T cells for 3
days in the ratio of 1:10. LPS-pulsed MoDCs induced T
cells to secrete IFN-γ compared to controls MoDCs (P =
0.023) in healthy subjects (Figure 4A). Crude mite extract-
pulsed MoDCs induced T cells to secrete large amount of
IFN-γ and IL-5 (P  = 0.013, < 0.001, respectively) and
higher lymphoproliferation (P = 0.002) compared to con-
trol MoDCs (Figure 4B). In allergic patients, LPS-pulsed
MoDCs and crude mite extract-pulsed MoDCs induced
higher T cell lymphoproliferation than control MoDCs (P
= 0.039, 0.008, respectively). IFN-γ secretion by T cells co-
cultured with LPS or crude mite extract stimulated MoDCs
was higher in healthy subjects than in allergic patients (P
= 0.015, 0.012, respectively). There was no difference in T
cell cytokine production (IFN-γ and IL-5) and lympho-
proliferation between MoDCs that were or were not
treated with CAPE in both healthy subjects and allergic
patients (Figure 4A and 4B).
CAPE inhibited IκBα phosphorylation in human MoDCs
Since LPS can induce DC maturation through NF-κB acti-
vation [33], we used LPS to activate the NF-κB pathway
and determine if CAPE could inhibit NF-κB activation in
MoDCs. IκBα phosphorylation, related to NF-κB activa-
tion, was assessed by Western blot. After pretreating
MoDCs with CAPE for 2 hours, LPS was added for 45 min-
utes to induce NF-κB activation. It was found that CAPE
inhibited cytosolic IκBα phosphorylation in a dose-
dependent manner (Figure 5A). CAPE could also inhibit
the IκBα degradation (see Additional file 1: Figure S1B).
CAPE inhibited NF-κB activation in human MoDCs
To monitor the inhibitory ability of CAPE on NF-κB trans-
location into the nucleus, MoDCs pretreated as men-
tioned were cultured with LPS for 2 hours. The nuclear
extracts were analyzed for NF-κB DNA binding by the
EMSA. It was found that CAPE inhibited NF-κB transloca-BMC Immunology 2009, 10:39 http://www.biomedcentral.com/1471-2172/10/39
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CAPE inhibited IL-12 p40, IL-12 p70, IL-10 and IP-10 production in human MoDCs Figure 1
CAPE inhibited IL-12 p40, IL-12 p70, IL-10 and IP-10 production in human MoDCs. Immature MoDCs (106 cells/
mL) were cultured for 48 hours either in the absence or presence of CAPE (10 μM) under LPS (100 ng/mL) or crude mite 
extract (100 μg/mL) stimulation. Cytokine levels in the supernatant from ten non-atopic healthy subjects and six mite-sensi-
tized allergic patients were measured by ELISA according to the manufacturer's instructions. *P < 0.05; **P < 0.01.BMC Immunology 2009, 10:39 http://www.biomedcentral.com/1471-2172/10/39
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tion and activation in a dose-dependent manner (Figure
5B). The binding of NF-κB was specific and could be
blocked by unlabeled, competing NF-κB oligonucleotide.
CAPE did not inhibit the phosphorylation of MAPK 
families in human MoDCs
Phosphorylation of p38 mitogen-activated protein kinase
(MAPK), p42/44 extracellular signal-regulated kinases
(ERK) and P46/54 c-Jun N-terminal kinases (JNK) repre-
senting 3 different MAPK activation pathways were evalu-
ated. The levels of MAPK phosphorylation in MoDCs
treated as described above (LPS stimulation for 45 min-
utes) were analyzed by Western blot analysis. It was found
that CAPE did not inhibit the phosphorylation of p38
MAPK, p42/44 ERK or P46/54 JNK (Figure 5C).
Discussion
The main purpose of this study is to elucidate the regula-
tory effect of CAPE on human MoDCs. First, the cytokine
(IL-12 p40, IL-12 p70, and IL-10) and chemokine (IP-10)
production from MoDCs were evaluated. In our study, we
used LPS as the stimulation other than crude mite extract
because LPS is known to be ubiquitously present in the
environment and induces Th1- and Th2-related cytokine
and chemokine expression [34]. We found that LPS could
induce MoDCs to secrete high levels of IL-12, IL-10 and
IP-10 in healthy subjects and allergic patients (Figure 1) as
previously stated [32,35,36]. Crude mite extract could
also stimulate MoDCs to secrete high levels of IL-12 p40
and IP-10 in healthy subjects but high levels of IL-10 and
IP-10 in allergic patients. The CAPE treatment could
inhibit IL-12 and IL-10 secretion under LPS or crude mite
extract stimulation in healthy subjects but only IL-10
secretion under crude mite extract stimulation in allergic
patients. CAPE could only inhibit IP-10 secretion under
crude mite extract stimulation but not LPS in both healthy
subjects and allergic patients. Because the large variation
was noted between individuals and the inhibitory effect of
CAPE was dose-dependent (data not shown), we specu-
lated that the higher concentration of CAPE may lead to
significant IL-12 inhibition in allergic patients.
IL-12, produced by mature DCs, has a central role in initi-
ating a specific T cell-mediated immune response [37,38],
driving Th1 cell activation and differentiation [39-42],
and inducing production of IFN-γ and lytic activity
[43,44] IL-10, the well known regulatory cytokine, can
have different functions in immune differentiation and
CAPE did not inhibit costimulatory molecule (such as CD86, CD80, and CD83) expression on MoDCs Figure 2
CAPE did not inhibit costimulatory molecule (such as CD86, CD80, and CD83) expression on MoDCs. Immature 
MoDCs from healthy subjects were cultured for 48 hours either in the absence or presence of CAPE (10 μM) under LPS (100 
ng/mL) or crude mite extract (100 μg/mL) stimulation. Surface markers were analyzed by flow cytometry. (A) Histogram of flu-
orescence intensity of HLA-DR, CD86, CD80 and CD83. The values shown in the flow cytometry profiles are the mean fluo-
rescence intensity (MFI) indexes. (B) MFI of HLA-DR, CD86, CD80, and CD83. Data shown represent mean ± SEM from three 
separate experiments. *P < 0.05; **P < 0.01.BMC Immunology 2009, 10:39 http://www.biomedcentral.com/1471-2172/10/39
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regulation. On one hand, IL-10 and TGF-β have been
shown to induce regulatory T cells. These two cytokines,
produced early in the infection could activate T cell sub-
sets such as IL-10 and IFN-γ producing T cells [45]. Neu-
tralization of IL-12 inhibited the generation of the double
producing T cell lines, indicating the role of IL-12 in
inducing IL-10 and IFN-γ producing T cells. Therefore, the
principle source of IL-10 in persistent infection may be T
cells that also produce IFN-γ, which was important in the
modulation of the inflammatory response [45]. On the
other hand, IL-10 produced by DCs and macrophages
promotes Th2 responses by abrogation of IL-12 genera-
tion [46]. DCs from IL-10 treated cultures can induce
naïve T cells to differentiate into IL-4-secreting T cells [47],
while DCs treated with anti-IL-10 Ab have an increased
capacity to activate allogeneic T cells and prime naïve T
cells to a more prominent Th1 polarization [48]. Further,
the IL-10-induced anergic state in human CD4+ T cells can
be reversed by mature DCs [49]. Therefore, the IL-10 pro-
duced by DCs may promote Th2 responses but not T cell
anergy when co-cultured with mature DCs. In the present
study, it appeared that CAPE inhibited cytokine produc-
tion by MoDCs without preference of Th1 or Th2 prone
cytokines in both healthy subjects and allergic patients.
IP-10 is a potent chemokine for activated T cells, natural
killer cells, and mast cells [50]. In individuals with estab-
lished allergic inflammation, IP-10 is capable of worsen-
ing preexisting asthmatic airway inflammation [51].
CAPE inhibited IP-10 production by crude mite extract-
stimulated MoDCs, which could prevent the IP-10
induced airway inflammation in asthmatic patients under
mite exposure. Therefore, CAPE inhibited cytokine and
chemokine production by MoDCs, and the inhibition was
extensive and may have influenced the T cell priming, acti-
vation, inflammatory cells recruitment and the further air-
way inflammation.
NF-κB activation may be responsible, in part, for
increased expression of many inflammatory genes in
asthma [52]. NF-κB normally binds to IκBα to inhibit NF-
The effect of CAPE on the phagocytic capacity of human MoDCs Figure 3
The effect of CAPE on the phagocytic capacity of human MoDCs. Immature MoDCs from healthy subjects were cul-
tured for 24 hours either in the absence or presence of CAPE (10 μM) under LPS (100 ng/mL) or crude mite extract (100 μg/
mL) stimulation. Cells were then incubated with FITC-dextran for 1 hour at 4°C (thin lines) or 37°C (thick lines). The values 
shown in the flow cytometry profiles are the MFI indexes. One representative of three independent experiments is shown.
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The effect of CAPE-treated MoDCs on T cell activation Figure 4
The effect of CAPE-treated MoDCs on T cell activation. Mature MoDCs (105 cells/mL) from eight non-atopic healthy 
subjects and four mite-sensitized allergic patients treated as indicated were co-cultured with autologous naïve CD4+ T cells 
(106 cells/mL). (A) Supernatants were analyzed for IFN-γ and IL-5, which were produced by activated T cells after 3 days of cul-
ture. (B) Tritiated(3H) thymidine incorporation was measured by liquid scintillation counting after 5 days of culture and 
expressed as mean counts per minute (cpm). *P < 0.05; **P < 0.01.BMC Immunology 2009, 10:39 http://www.biomedcentral.com/1471-2172/10/39
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The effect of CAPE on the NF-κB and MAPK signaling pathway Figure 5
The effect of CAPE on the NF-κB and MAPK signaling pathway. Human MoDCs from healthy subjects were pre-
treated with CAPE in the indicated concentration for 2 hours, then stimulated by LPS (100 ng/mL) for 45 minutes. Cell lysate 
were collected and the levels of phosphorylation of (A) IκBα and (C) MAPK family (p38 MAPK, p42/44 ERK, and p46/54 JNK 
kinase) were assayed by Western blotting with indicated Abs. Anti-α-tubulin mAb and anti-total p38 polyclonal Ab were for 
internal control. (B) The pretreated MoDCs as mentioned were stimulated by LPS (100 ng/mL) for 2 hours and nuclear frac-
tions were prepared and analyzed for NF-κB binding activity by EMSA. To assess the specificity of the binding, 100-fold excess 
of cold NF-κB probe or mutant probe was added to the LPS condition. One representative of at least three independent 
experiments is shown.BMC Immunology 2009, 10:39 http://www.biomedcentral.com/1471-2172/10/39
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κB nuclear translocation from the cytosol to the nucleus
for further enhancement of inflammatory and associated
gene transcription. Once cells are exposed to inflamma-
tory stimuli such as LPS, IκBα is phosphorylated by IKK
complex and degraded, leading to the nuclear transloca-
tion of activated NF-κB [53-56]. Different inhibitory
results of CAPE on NF-κB signaling pathway were noted
in the literatures. In T cells, the direct inhibition of NF-κB
nuclear translocation [18,20], and the indirect inhibition
of IκBα phosphorylation [20] were noted. In these two
articles, CAPE could inhibit IκBα resynthesis instead of
cytosolic IκBα degradation [18,20]. However, the inhibi-
tory effect of IκBα degradation of CAPE was observed in
human middle ear epithelial cells [57] and gastric epithe-
lial cells [58]. CAPE inhibited IκB degradation in mono-
cytic cells but not astroglial cells, in which the suppression
of activated IKK was shown [59]. It seemed that in differ-
ent cells and possible different concentrations of CAPE
(10 μM ~100 μM) would result in different inhibitory
mechanisms. In the present study, we found that CAPE
inhibited IκBα phosphorylation (Figure 5A) and NF-κB
activation (Figure 5B) in human MoDCs in a dose-
dependent manner. CAPE could also inhibit IκBα degra-
dation (see Additional file 1 Figure S1B). We speculate
that the inhibition of IκBα phosphorylation leads to the
inhibition of IκBα degradation, so the nuclear transloca-
tion of NF-κB is inhibited for further enhancement of
inflammatory and associated gene transcription. Jayaku-
mar  et al. also reported that pretreatment with CAPE
blocked NF-κB p50, NF-κB p65 nuclear translocation in
human MoDCs [30]. Since the promoters of hIL-12 p35
and hIL-12 p40 gene contain κB binding sites [60], and
previous studies implicates the specific role of NF-κB fac-
tors in IL-12 transcription [30,61,62], we also suggested
that the inhibition of NF-κB signaling by CAPE might
result in the decreased production of IL-12 p40 and p70.
The MAPK signaling in the MoDCs maturation may also
induce the inflammatory cytokine production [63]. Here,
we found that CAPE did not appear to alter the MAPK sig-
naling pathway in human MoDCs, while p38 MAPK and
ERK were activated in C6 glioma cells by the treatment of
CAPE [64]. Therefore, new experiments addressing the
detailed mechanism of inhibition effect of CAPE in
cytokine and chemokine production are required.
Upon maturation, DCs can present captured antigens to T
cells to induce proliferation and cytokine production in T
cells [27]. To mimic in vivo system, we chose "autologous"
naïve CD4+ T cells for coculture to evaluate the ability of
antigen presentation and T cell priming of MoDCs. Sur-
prisingly, CAPE did not inhibit the cytokine production of
T cells (Figure 4A) as seen in MoDCs. The lymphoprolif-
eration assay (a marker of T cell activation triggered by
APCs) [65] was not inhibited in both healthy subjects and
allergic patients when co-cultured with CAPE treated DCs
either (Figure 4B). This result might be explained by the
fact that the coculture system was in a "renewed" culture
medium (2% human AB serum of RPMI). Therefore, the
effect of decreased cytokine and chemokine production
by MoDCs on T cell priming would be abolished in the
experiment. As CAPE did not inhibit the upregulation of
MHC molecules and costimulatory molecules in mature
MoDCs, the antigen presenting ability of MoDCs in the
present study were not expected to differ.
It is interesting about the polarization of crude mite
extract. It induced MoDCs to produce large amount of IL-
12 p40 but little IL-10 in healthy subjects, and lower IL-12
p40 but higher IL-10 in allergic patients, which indicated
that crude mite extract was Th2-prone in allergic patients
but not in non-atopic healthy subjects. The phenomenon
was also proved in cocultured naïve CD4+ T cells. The
lower IFN-γ/IL-5 in allergic patients indicated a Th2 polar-
ization while the higher IFN-γ/IL-5 in healthy subjects
favored a Th1 polarization. The different polarizations by
Der p-pulsed MoDCs due to the allergic status of the
donors were also reported previously [35,36]. These stud-
ies used purified Der p 1 for stimulation. They all found
that IL-4 or IL-5 was increased in co-cultured autologous
CD4+ T cells from mite-sensitized allergic patients while
IFN-γ was increased in those from healthy subjects.
The major limitation of our present study is failure of
mimicking microenvironment of DC-T cell interaction in
vivo with cytokine and chemokine in which immunity can
develop [66]. Therefore, the effect of the decreased IL-12,
IL-10 and IP-10 production by MoDCs treated with CAPE
in priming T cells cannot be surveyed in the present study.
IL-12 is related to the T cell polarizing and T cell survival
[67], thus the decreased IL-12 in microenvironment may
influence the T cell activation and proliferation. To deter-
mine whether the decreased cytokine secretion of MoDCs
would influence the T cells activation, we collected the
supernatant of pulsed MoDCs mixed with serum free
RPMI 1640 (1:1) to culture autologous naïve CD4+ T cells.
The cytokine production and lymphoproliferation were
inhibited in CAPE treated group (data not shown). How-
ever, the CAPE was in the supernatant and could directly
inhibit the T cells activation through NF-κB and NFAT
pathway [19,20]. The decreased activation of T cells may
be due to both the decreased cytokine and chemokine
secretion from MoDCs and the CAPE direct effect. The
other limitation is that the in vitro human MoDCs cannot
represent the in vivo tissue DCs. To study the effect of
CAPE on the function of circulating DCs will be the future
work.
Conclusion
Our results showed that CAPE significantly inhibited IL-
12 p40, IL-12 p70, IL-10 protein expression in mature
healthy human MoDCs stimulated by lipopolysaccha-
rides (LPS) and IL-12 p40, IL-10, IP-10 stimulated byBMC Immunology 2009, 10:39 http://www.biomedcentral.com/1471-2172/10/39
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crude mite extract. CAPE significantly inhibited IL-10 and
IP-10 but not IL-12 expression in allergic patients' MoDCs
stimulated by crude mite extract. In contrast, the upregu-
lation of costimulatory molecules in mature MoDCs was
not suppressed by CAPE. Therefore, the antigen presenta-
tion ability of MoDCs through MHC peptide complex and
costimulatory molecules was not changed in this study
after evaluating T cell lymphoproliferation and cytokine
production. The mechanism of the inhibition of cytokine
and chemokine production in MoDCs was thought to be
related to NF-κB signaling, but not the MAPK pathway.
The findings of this study provide new information and
evidence for regulatory effect of CAPE on MoDCs relevant
to the pathogenesis of allergic airway disease, such as
asthma and allergic rhinitis. Further, it is possible to sug-
gest that CAPE and propolis might be useful in the man-
agement of allergic disorders since CAPE inhibited
cytokine and chemokine production in MoDCs and thus
resulted in a decrease in downstream inflammatory proc-
ess.
Methods
Human subjects
The mite-sensitized allergic patients [three had allergic
rhinitis, three had asthma, and all had 4+ of mite-specific
IgE (MAST, HITACHI CLA test)] and non-atopic healthy
subjects were enrolled for peripheral blood sampling. This
study was approved by the Research Ethics Committee of
the National Taiwan University Hospital and informed
consent was obtained from all subjects.
Reagents
CAPE and Escherichia coli LPS (L8274, E. coli) were pur-
chased from Sigma-Aldrich Chemical Co. (St. Louis, MO).
CAPE was dissolved in DMSO. Cells without CAPE treat-
ment were treated with DMSO only (0.1% of culture
medium, v/v). Isotopes were obtained from Amersham
Corp. (Arlington Heights, IL).
Crude mite extract from Dermatophagoides 
pteronyssinus
Lyophilized house dust mite (Dermatophagoides pteronyssi-
nus) was purchased from Allergon (Angelholm, Sweden).
The allergen was prepared as described previously [68].
Briefly, 1 g of lyophilized mite body was defatted with 100
mL ether, homogenized and stirred continuously in 25
mL phosphate-buffered saline (PBS) for 48 hours at 4°C.
After centrifugation (12000 g for 30 minutes), the crude
mite extract was dialysed with PBS and then dissolved in
PBS and stored at -20°C.
Isolation of human peripheral monocytes and generation 
of human MoDCs
MoDCs were generated from peripheral monocytes, as
described previously [32]. Peripheral mononuclear cells
(PBMCs) were isolated from heparinized peripheral
blood by Ficoll-Hypaque (GE Healthcare, Buckingham-
shire, UK) density gradient centrifugation (400 g for 30
minutes at room temperature). The mononuclear cells
layer was washed twice with sterile Hank's solution
(Sigma-Aldrich). CD14+ cells were purified by positive
selection using anti-CD14+  conjugated magnetic
microbeads by autoMACS according to the manufac-
turer's protocol (Miltenyi Biotec, Auburn, CA). The
CD14+  monocytes were then cultured in RPMI 1640
medium (SAFC Biosciences, Lenexa, Kansas) containing
10% fetal calf serum (FCS), 2 mM L-glutamine, 100 U/mL
penicillin, 100 U/mL streptomycin, and 25 mM HEPES
with granulocyte macrophage-colony stimulating factor
(GM-CSF; 800 U/mL) and IL-4 (200 U/mL) in 24-well
plates (Costar, Cambridge, MA) plated at a concentration
of 106  cells/mL for 5 days (37°C/5% CO2). Human
MoDCs were routinely used at day 6 of culture. Immature
MoDCs were treated with LPS (100 ng/mL) or crude mite
extract (100 μg/mL) in the absence or presence of CAPE
(10 μM) for an additional 2 days to obtain mature DCs.
The doses and time-points chosen were according to the
literature [20,32] and further confirmed in the pilot exper-
iments (data not shown).
Co-culture of MoDCs and autologous T cells
PBMCs were obtained as described above and naïve CD4+
T cells were purified from PBMCs using a naïve CD4+ T
cell isolation kit (Miltenyi Biotec) according to the manu-
facturer's protocol. Autologous naïve CD4+ T cells were
cultured with RPMI 1640 with 2% human AB serum in
the concentration of 106 cells/mL in 96-well round bot-
tom plates in triplicate for 3 days in combination with
mature MoDCs (105 cells/mL). Tritiated thymidine (1
μCi/well, New England Nuclear, Boston, MA) incorpora-
tion for 16 hours was determined with a liquid scintilla-
tion counter.
Determination of cytokine and chemokine levels
Concentrations of IFN-γ, IL-5, IL-10, IL-12 p40, IL-12 p70,
and IP-10 in the culture supernatant from MoDCs or T
cells were assayed by an enzyme-linked immunosorbent
assay (ELISA) kit (R&D Systems, Minneapolis, MN)
according to each of the manufacturer's protocol.
Flow cytometry analysis
MoDCs were harvested and washed with cold buffer (PBS
containing 2% FCS and 0.1% sodium azide). Cells were
stained with the monoclonal antibodies of CD14, HLA-
DR, CD80, CD83 or CD86 (Becton Dickinson, San Jose,
CA) or isotype-matched controls for 30 minutes on ice.
Stained cells were then washed and resuspended in cold
buffer and analyzed with a FACSort cell analyzer (Becton
Dickinson). More than 1 × 104 cells were analyzed for
each sample and the results were processed by Cellquest
software (Becton Dickinson).BMC Immunology 2009, 10:39 http://www.biomedcentral.com/1471-2172/10/39
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Phagocytic capacity analysis
MoDCs were washed twice, resuspended in RPMI 1640
medium containing 10% FCS and rest on ice for 30 min-
utes. The cells were then incubated with FITC-labeled dex-
tran (0.2 mg/mL; Invitrogen, Carlsbad, CA) at 4°C or
37°C for 1 hour. Finally, the cells were washed thrice with
cold buffer and analyzed with a FACSort cell analyzer, as
described above.
Western blotting
Human MoDCs were pre-treated with CAPE (0, 5, 10 or
20 μM) for 2 hours. LPS (100 ng/mL) was then added for
45 minutes (37°C/5% CO2), then the total cellular extract
was prepared using Gold lysis buffer [10% glycerol, 1%
Triton X-100, 1 mM sodium orthovanadate, 1 mM EGTA,
5 mM EDTA, 10 mM NaF, 1 mM sodium pyrophosphate,
20 mM Tris-HCl, pH 7.9, 100 μM β-glycerophosphate,
137 mM NaCl, 1 mM phenylmethylsulfonyl fluoride
(PMSF), 10 μg/mL aprotinin, and 10 μg/mL leupeptin] for
30 minutes at 4°C. The cell lysate was clarified by centrif-
ugation at 12,000 g for 15 minutes at 4°C. Total protein
(35 μg) was separated on 10% sodium dodecyl sulfate
(SDS)-polyacrylamide minigels and transferred to Immo-
bilon polyvinylidene difluoride membrane (Millipore,
Bedford, MA). The membrane was incubated for 1 hour at
room temperature with 5% nonfat dry milk in PBS to
block nonspecific immunoglobulins, then incubated with
anti-α-tubulin mAb (Santa Cruz Biotechnology, Santa
Cruz, California), anti-IκBα, anti-IκBα-P, anti-p38-P,
anti-p42/44-P, anti-p46/54-P, or anti-total p38 polyclo-
nal antibodies (Cell Signaling Technology, Beverly, MA).
Immunodetection was carried out by an Amersham
enhanced chemiluminescence plus system (GE Health-
care). The time-points chosen were according to the liter-
ature [20,32] and further confirmed in the pilot
experiments (see Additional file 1: Figure S1).
Preparation of nuclear extracts and electrophoretic 
mobility shift assay (EMSA)
Nuclear extracts were prepared by NE-PER nuclear and
cytoplasmic extraction reagent kit (Pierce Biotechnology,
Rockford, IL) according to the manufacturer's protocol.
Each 5 μg nuclear extract was mixed with the labeled dou-
ble-stranded NF-κB oligonucleotide, 5'-AGTTGAG-
GGGACTTTCCCAGGC-3', and incubated at room
temperature for 20 min. The incubation mixture included
1 μg of poly (dI-dC) in a binding buffer (25 mM HEPES,
pH 7.9, 0.5 mM EDTA, 0.5 mM DTT, 1% Nonidet P-40,
5% glycerol, and 50 mM NaCl). The DNA-protein com-
plex was electrophoresed on 4.5% non-denaturing poly-
acrylamide gels in 0.5× TBE buffer (0.0445 M Tris, 0.0445
M borate, 0.001 M EDTA). A double-stranded mutated
oligonucleotide, 5'-AGTTGAGGCGACTTTCCCAGGC-3',
was used to examine the specificity of the binding of NF-
κB to DNA. The specificity of binding was also examined
by comparison with the unlabelled oligonucleotide.
Statistics
Raw data were expressed as mean ± standard error of
mean (SEM) and were analyzed by the Student's t test to
determine statistical differences between experimental
groups. P-values lower than 0.05 were considered to be
significant.
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